The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with
Vinorelbine for Second-line Therapy and Beyond in HER2-positive
Metastatic Breast Cancer: A Single-institution Clinical Experience

Fan      Wu; Mulan      Chen; Lili      Wang; Nani      Li; Xiufeng      Wu; Xinhua      Chen; Yi      Hong; Chongyin      Li; Lin      Lin; Kan      Chen; Weiwei      Huang; Jian      Liu

doi:10.2174/0115680096248592231016065117

Abstract

Background and Objectives: This study aimed to observe the efficacy and safety of inetetamab and pyrotinib in combination with vinorelbine in second-line therapy and beyond in HER2-positive metastatic breast cancer (MBC).

Methods: Patients with HER2-positive MBC admitted to our hospital from January 2016 to December 2021 were selected. For patients who could not receive antibody‒drug conjugates (ADCs) during second-line (2^nd-line) or third-line and beyond (≥ 3^rd-line) anti-HER2 therapy, inetetamab + pyrotinib + vinorelbine was used for treatment until unacceptable adverse events occurred or the disease progressed, as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 every 2 cycles. The progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR), and adverse reactions were recorded. Multivariate Cox regression analysis was performed to explore the prognostic factors influencing the curative effect.

Results: Overall, 52 patients were included; 13 patients received 2^nd-line treatment, and 39 patients received ≥ 3^rd-line treatment. The median PFS (mPFS) for all patients treated with inetetamab + pyrotinib + vinorelbine was 7 months. The mPFS of the 2^nd-line subgroup was significantly better than that of the ≥ 3^rd-line subgroup (17 vs. 5 months, P = 0.001). The mPFS of the subgroups that received trastuzumab (H) or trastuzumab and pertuzumab (HP) only was significantly better than that of the H or HP and tyrosine kinase inhibitor (TKI) subgroups (8 vs. 5 months, P = 0.030). The mPFS of the HER2 resistance subgroup was better than that of the HER2 refractoriness subgroup (14 vs. 7 months, P = 0.025). Cox regression analysis showed that the treatment line (2^nd-line more so than ≥ 3^rd-line) was an independent prognostic factor for PFS. In addition, the ORR and CBR of 2^nd-line patients were significantly higher than those of ≥ 3^rd-line patients (69.2% vs. 30.8% and 92.3% vs. 64.1%, respectively). The most common hematological toxicities were leukopenia and neutropenia, and the most common nonhematological toxicity was diarrhea.

Conclusion: Inetetamab and pyrotinib in combination with vinorelbine have good efficacy in ≥ 2^nd-line treatment of HER2-positive MBC with controllable toxicity, and the combination is a new treatment option, especially for patients who cannot use ADCs in 2^nd-line treatment.

« Previous Next »

Graphical Abstract

[1]
Wang, J.; Xu, B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct. Target. Ther.,  2019, 4(1), 34.
 [http://dx.doi.org/10.1038/s41392-019-0069-2] [PMID:  31637013]

[2]
Gradishar, W.J.; Moran, M.S.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K.H.; Blair, S.L.; Burstein, H.J.; Dang, C.; Elias, A.D.; Giordano, S.H.; Goetz, M.P.; Goldstein, L.J.; Hurvitz, S.A.; Isakoff, S.J.; Jankowitz, R.C.; Javid, S.H.; Krishnamurthy, J.; Leitch, M.; Lyons, J.; Matro, J.; Mayer, I.A.; Mortimer, J.; O’Regan, R.M.; Patel, S.A.; Pierce, L.J.; Rugo, H.S.; Sitapati, A.; Smith, K.L.; Smith, M.L.; Soliman, H.; Stringer-Reasor, E.M.; Telli, M.L.; Ward, J.H.; Wisinski, K.B.; Young, J.S.; Burns, J.L.; Kumar, R. NCCN Guidelines® insights: Breast cancer, version 4.2021. J. Natl. Compr. Canc. Netw.,  2021, 19(5), 484-493.
 [http://dx.doi.org/10.6004/jnccn.2021.0023] [PMID:  34794122]

[3]
Chudasama, R.; Fenton, M.A.; Dizon, D.S. Guidelines of Chinese Society of Clinical Oncology (CSCO) on diagnosis and treatment of breast cancer: An appraisal. Transl. Breast Cancer Res.,  2020, 1, 24.
 [http://dx.doi.org/10.21037/tbcr-2020-3]

[4]
Swain, S.M.; Miles, D.; Kim, S.B. Im, Y.H.; Im, S.A.; Semiglazov, V.; Ciruelos, E.; Schneeweiss, A.; Loi, S.; Monturus, E.; Clark, E.; Knott, A.; Restuccia, E.; Benyunes, M.C.; Cortés, J.; Agajanian, R.; Ahmad, R.; Aktas, B.; Alencar, V.H.; Amadori, D.; Andrade, J.; André Franke, F.; Angiolini, C.; Aogi, K.; Armor, J.; Arpornwirat, W.; Assersohn, L.; Audeh, W.; Aulitzky, W.; Azevedo, S.; Bartoli, M.A.; Batista Lopez, N.; Bianconi, M.; Biganzoli, L.; Birhiray, R.; Bitina, M.; Blachy, R.; Blackwell, K.; Blanchard, R.; Blanchet, P.; Boiangiu, I.; Bower, B.; Brezden-Masley, C.; Brufsky, A.; Budde, L.; Caguioa, P.; Calvo, L.; Campone, M.; Carroll, R.R.; Castro, H.; Chan, V.; Charu, V.; Cinieri, S.; Clemens, M.; Conejo, E.A.; Côrtes, E.; Coudert, B.; Cronemberger, E.; Cubero, D.; Dakhil, S.; Daniel, B.; Davidson, N.; De Fatima Gaui, M.; De La Cruz, S.; Del Pilar, M.; Delgado, G.; Ellerton, J.A.; Estuardo, C.; Fehrenbacher, L.; Ferrero, J-M.; Flynn, P.J.; Foszczynska-Kloda, M.; Franco, S.; Fujii, H.; Gallagher, C.; Gamucci, T.; Giacomi, N.; Gil I Gil, M.; Gonzalez Martin, A.; Gorbunova, V.; Gotovkin, E.; Green, N.; Grincuka, E.; Grischke, E-M.; Hansen, V.; Hargis, J.; Hauschild, M.; Hegg, R.; Hendricks, C.; Hermann, R.; Hoff, P.; Horiguchi, J.; Hornedo Muguiro, J.; Iacobelli, S.; Inoue, K.; Ismael, G.; Itoh, Y.; Iwata, D.H.; Jendiroba, D.; Jochim, R.; Jones, A.; Just, M.; Kallab, A.; Karwal, M.; Kashiwaba, M.; Kato, G.; Kaufman, P.A.; Kellokumpu-Lehtinen, P.; Kirsch, A.; Kiselev, I.; Klein, P.; Kohno, N.; Kopp, M.; Kostovska-Maneva, L.; Kotliar, M.; Kudaba, I.; Kümmel, S.; Kuroi, K.; Lacava, J.; Latini, L.; Lee, S.C.; Lichinitser, M.; Lobo, C.; Maintz, C.; Maneecahvakajorn, J.; Marmé, A.; Martinez, G.; Masuda, N.; Matwiejuk, M.; Merculov, V.; Michaelson, R.; Miguel, L.; Monroy, H.; Montemurro, F.; Morales, S.; Moura, R.; Mueller, V.; Mulatero, C.; Nakagami, K.; Nakayama, T.; Neidhart, J.; Nguyen, A.; Nishimura, R.; Ogata, H.; O’reilly, S.; O’rourke, T.; Otero Reye, D.; Ouyang, X.; Patel, R.; Patel, T.; Pedrini, J.L.; Pereira, R.; Perez, A.; Peterson, C.; Pienkowski, T.; Pinczowski, H.; Polikoff, J.; Polkowski, W.; Price, P.E.; Prill, S.; Priou, F.; Purkalne, G.; Pyrhoenen, S.; Quackenbush, R.; Rai, Y.; Ribelles, N.; Ro, J.; Robinson, A.; Robles, R.; Rodriguez, G.; Roman, L.; Saji, S.; Sanchez-Rovira, P.; Sato, N.; Schmidt, M.; Schumacher, C.; Senecal, F.; Sharma, P.; Shen, Z.; Shirinkin, V.; Simoncini, E.; Sirisinha, T.; Smith, R.; Sohn, J-H.; Soldic, Z.; Soria, T.; Spicer, D.; Srimuninnimit, V.; Sriuranpong, V.; Staroslawska, E.; Stefanovski, P.; Sunpaweravong, P.; Taguchi, J.; Takeda, K.; Tellez-Trevilla, G.; Thomas, R.; Thomssen, C.; Toache, Z.; Tokuda, Y.; Tomczak, P.; Tosello, C.; Tsugawa, K.; Tudtud, D.; Ueno, T.; Van Eyll, B.; Varela, M.; Vasev, N.; Vrbanec, D.; Wang, X.; Wang, L.; Watanabe, J.; Waterhouse, D.; Wesenberg, B.; Wheatley, D.; Wong, Z.W.; Yadav, S.; Yadav, S.; Yardley, D.; Yau, T-K.; Yeo, W.; Ying, C.; Youn Oh, D. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol.,  2020, 21(4), 519-530.
 [http://dx.doi.org/10.1016/S1470-2045(19)30863-0] [PMID:  32171426]

[5]
Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.Y.; Diéras, V.; Guardino, E.; Fang, L.; Lu, M.W.; Olsen, S.; Blackwell, K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med.,  2012, 367(19), 1783-1791.
 [http://dx.doi.org/10.1056/NEJMoa1209124] [PMID:  23020162]

[6]
Cortés, J.; Kim, S.B.; Chung, W.P. Im, S.A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.M.; Petry, V.; Chung, C.F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med.,  2022, 386(12), 1143-1154.
 [http://dx.doi.org/10.1056/NEJMoa2115022] [PMID:  35320644]

[7]
Blackwell, K.L.; Burstein, H.J.; Storniolo, A.M.; Rugo, H.S.; Sledge, G.; Aktan, G.; Ellis, C.; Florance, A.; Vukelja, S.; Bischoff, J.; Baselga, J.; O’Shaughnessy, J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol.,  2012, 30(21), 2585-2592.
 [http://dx.doi.org/10.1200/JCO.2011.35.6725] [PMID:  22689807]

[8]
Murthy, R.K.; Loi, S.; Okines, A.; Paplomata, E.; Hamilton, E.; Hurvitz, S.A.; Lin, N.U.; Borges, V.; Abramson, V.; Anders, C.; Bedard, P.L.; Oliveira, M.; Jakobsen, E.; Bachelot, T.; Shachar, S.S.; Müller, V.; Braga, S.; Duhoux, F.P.; Greil, R.; Cameron, D.; Carey, L.A.; Curigliano, G.; Gelmon, K.; Hortobagyi, G.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Palanca-Wessels, M.C.; Walker, L.; Feng, W.; Winer, E.P. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med.,  2020, 382(7), 597-609.
 [http://dx.doi.org/10.1056/NEJMoa1914609] [PMID:  31825569]

[9]
de Azambuja, E.; Holmes, A.P.; Piccart-Gebhart, M.; Holmes, E.; Di Cosimo, S.; Swaby, R.F.; Untch, M.; Jackisch, C.; Lang, I.; Smith, I.; Boyle, F.; Xu, B.; Barrios, C.H.; Perez, E.A.; Azim, H.A., Jr; Kim, S.B.; Kuemmel, S.; Huang, C.S.; Vuylsteke, P.; Hsieh, R.K.; Gorbunova, V.; Eniu, A.; Dreosti, L.; Tavartkiladze, N.; Gelber, R.D.; Eidtmann, H.; Baselga, J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol.,  2014, 15(10), 1137-1146.
 [http://dx.doi.org/10.1016/S1470-2045(14)70320-1] [PMID:  25130998]

[10]
Carey, L.A.; Berry, D.A.; Cirrincione, C.T.; Barry, W.T.; Pitcher, B.N.; Harris, L.N.; Ollila, D.W.; Krop, I.E.; Henry, N.L.; Weckstein, D.J.; Anders, C.K.; Singh, B.; Hoadley, K.A.; Iglesia, M.; Cheang, M.C.U.; Perou, C.M.; Winer, E.P.; Hudis, C.A. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J. Clin. Oncol.,  2016, 34(6), 542-549.
 [http://dx.doi.org/10.1200/JCO.2015.62.1268] [PMID:  26527775]

[11]
Ding, X.; Mo, W.; Xie, X.; Wang, O.; Ding, Y.; Zhao, S.; He, X.; Feng, W.; Zou, D.; Yang, H. Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial. J. Clin. Oncol.,  2021, 39(15_suppl ), (Suppl.), 574-574.
 [http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.574]

[12]
Zhou, X.; Yu, J.; Wang, W.; Song, G.; Wang, X.; Ren, J.; Di, L.; Wang, X. A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients. Springerplus,  2015, 4(1), 803.
 [http://dx.doi.org/10.1186/s40064-015-1603-5] [PMID:  26702392]

[13]
Bian, L.; Xu, B.H.; Di, L.J.; Wang, T.; Wang, X.J.; Jiao, S.C.; Yang, J.L.; Tong, Z.S.; Liu, J.; Feng, J.F.; Liu, D.G.; Yu, Q.T.; Liu, Y.P.; Ma, Y.; Yu, H.; Jiang, Z.F. Phase III randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study. Zhonghua Yi Xue Za Zhi,  2020, 100(30), 2351-2357.
 [PMID:  32791810]

[14]
Xu, B.; Yan, M.; Ma, F.; Hu, X.; Feng, J.; Ouyang, Q.; Tong, Z.; Li, H.; Zhang, Q.; Sun, T.; Wang, X.; Yin, Y.; Cheng, Y.; Li, W.; Gu, Y.; Chen, Q.; Liu, J.; Cheng, J.; Geng, C.; Qin, S.; Wang, S.; Lu, J.; Shen, K.; Liu, Q.; Wang, X.; Wang, H.; Luo, T.; Yang, J.; Wu, Y.; Yu, Z.; Zhu, X.; Chen, C.; Zou, J. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol.,  2021, 22(3), 351-360.
 [http://dx.doi.org/10.1016/S1470-2045(20)30702-6] [PMID:  33581774]

[15]
Cardoso, F.; Paluch-Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M.S.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.S.; Biganzoli, L.; Boyle, F.; Cardoso, M.J.; Carey, L.A.; Cortés, J.; El Saghir, N.S.; Elzayat, M.; Eniu, A.; Fallowfield, L.; Francis, P.A.; Gelmon, K.; Gligorov, J.; Haidinger, R.; Harbeck, N.; Hu, X.; Kaufman, B.; Kaur, R.; Kiely, B.E.; Kim, S.B.; Lin, N.U.; Mertz, S.A.; Neciosup, S.; Offersen, B.V.; Ohno, S.; Pagani, O.; Prat, A.; Penault-Llorca, F.; Rugo, H.S.; Sledge, G.W.; Thomssen, C.; Vorobiof, D.A.; Wiseman, T.; Xu, B.; Norton, L.; Costa, A.; Winer, E.P. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of oncology,  2020, 31(12), 1623-1649.

[16]
Wong, H.; Leung, R.; Kwong, A.; Chiu, J.; Liang, R.; Swanton, C.; Yau, T. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer. Oncologist,  2011, 16(11), 1535-1546.
 [http://dx.doi.org/10.1634/theoncologist.2011-0165] [PMID:  22020213]

[17]
Lyman, G.H. Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl. Compr. Canc. Netw.,  2009, 7(1), 99-108.
 [http://dx.doi.org/10.6004/jnccn.2009.0009] [PMID:  19176210]

[18]
Hess, L.M.; Brnabic, A.; Mason, O.; Lee, P.; Barker, S. Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. J. Cancer,  2019, 10(16), 3717-3727.
 [http://dx.doi.org/10.7150/jca.32205] [PMID:  31333789]

[19]
Colomer, R.; Hall, P.; Szkultecka-Debek, M.; Bondi, R.C.; Flinois, A.; Auziere, S.; Le Cléac’h, J.Y. Real-world treatment in patients with HER2+ metastatic breast cancer. Breast Cancer Res. Treat.,  2018, 168(1), 197-205.
 [http://dx.doi.org/10.1007/s10549-017-4567-z] [PMID:  29170976]

[20]
Ibragimova, K.I.E.; Geurts, S.M.E.; Croes, S.; Erdkamp, F.; Heijns, J.B.; Tol, J.; Vriens, B.E.P.J.; Aaldering, K.N.A.; Dercksen, M.W.; Pepels, M.J.A.E.; Peters, N.A.J.B.; van de Winkel, L.; Tilli, D.J.P.; Vriens, I.J.H.; de Boer, M.; Tjan-Heijnen, V.C.G. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Res. Treat.,  2021, 188(2), 571-581.
 [http://dx.doi.org/10.1007/s10549-021-06178-8] [PMID:  33743103]

[21]
Le, Q.A.; Bae, Y.H.; Kang, J.H. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res. Treat.,  2016, 159(3), 565-573.
 [http://dx.doi.org/10.1007/s10549-016-3958-x] [PMID:  27572338]

[22]
Squires, H.; Stevenson, M.; Simpson, E.; Harvey, R.; Stevens, J. Trastuzumab emtansine for treating her2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics,  2016, 34(7), 673-680.
 [http://dx.doi.org/10.1007/s40273-016-0386-z] [PMID:  26892972]

[23]
Houten, R.; Fleeman, N.; Mahon, J.; Chaplin, M.; Edwards, K.; Beale, S.; Boland, A.; Dundar, Y.; Marsden, A.; Malik, Z.; Palmieri, C. Trastuzumab deruxtecan for treating her2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies: An evidence review group perspective of a nice single technology appraisal. PharmacoEconom. Open,  2023, 7(3), 345-358.
 [http://dx.doi.org/10.1007/s41669-023-00405-2] [PMID:  37084172]

[24]
Li, J.; Shao, Z.; Xu, B.; Jiang, Z.; Cui, S.; Zhang, J.; Liao, N.; Jiang, J.; Wang, Y.; Ouyang, Q.; Ying, Z. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China. Medicine (Baltimore),  2018, 97(21), e10350.
 [http://dx.doi.org/10.1097/MD.0000000000010350] [PMID:  29794725]

[25]
Lin, N.U.; Murthy, R.K.; Anders, C.K.; Borges, V.F.; Hurvitz, S.A.; Loi, S.; Abramson, V.G.; Bedard, P.L.; Oliveira, M.; Zelnak, A.B.; DiGiovanna, M.; Bachelot, T.; Chien, A.J.; O’Regan, R.; Wardley, A.M.; Müller, V.; Carey, L.A.; McGoldrick, S.M.; An, G.; Winer, E.P. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). J. Clin. Oncol.,  2020, 38(15_suppl), (Suppl.), 1005.
 [http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.1005]

[26]
Fernandez-Martinez, A.; Krop, I.E.; Hillman, D.W.; Polley, M.Y.; Parker, J.S.; Huebner, L.; Hoadley, K.A.; Shepherd, J.; Tolaney, S.; Henry, N.L.; Dang, C.; Harris, L.; Berry, D.; Hahn, O.; Hudis, C.; Winer, E.; Partridge, A.; Perou, C.M.; Carey, L.A. Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J. Clin. Oncol.,  2020, 38(35), 4184-4193.
 [http://dx.doi.org/10.1200/JCO.20.01276] [PMID:  33095682]

[27]
Wu, J.; Jiang, Z.; Liu, Z.; Yang, B.; Yang, H.; Tang, J.; Wang, K.; Liu, Y.; Wang, H.; Fu, P.; Zhang, S.; Liu, Q.; Wang, S.; Huang, J.; Wang, C.; Wang, S.; Wang, Y.; Zhen, L.; Zhu, X.; Wu, F.; Lin, X.; Zou, J. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med.,  2022, 20(1), 498.
 [http://dx.doi.org/10.1186/s12916-022-02708-3] [PMID:  36575513]

[28]
Wang, X-W.; Liu, P-P. LI, F.-H.; Tan, Q.-Q. Evaluation of critical quality attributes of an anti-HER2 humanized monoclonal antibody drug. Chung Kuo Yao Hsueh Tsa Chih,  2015, 50(12), 1054-1061.

[29]
Wang, T.; Zhang, P.; Di, L.; Wang, X.; Yang, J.; Tong, Z.; Liu, J.; Feng, J.; Liu, D.; Yu, Q.; Liu, Y.; Yu, H.; Jiang, Z. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study. Transl. Breast Cancer Res.,  2022, 3, 15.
 [http://dx.doi.org/10.21037/tbcr-21-42]

[30]
De Maio, E.; Pacilio, C.; Gravina, A.; Morabito, A.; Di Rella, F.; Labonia, V.; Landi, G.; Nuzzo, F.; Rossi, E.; Silvestro, P.; Botti, G.; Di Bonito, M.; Curcio, M.P.; Formichelli, F.; La Vecchia, F.; Staiano, M.; Maurea, N.; D’Aiuto, G.; D’Aiuto, M.; Thomas, R.; Signoriello, G.; Perrone, F.; de Matteis, A. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer,  2007, 7(1), 50.
 [http://dx.doi.org/10.1186/1471-2407-7-50] [PMID:  17374151]

[31]
Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.,  2001, 344(11), 783-792.
 [http://dx.doi.org/10.1056/NEJM200103153441101] [PMID:  11248153]

[32]
Li, X.; Yang, C.; Wan, H.; Zhang, G.; Feng, J.; Zhang, L.; Chen, X.; Zhong, D.; Lou, L.; Tao, W.; Zhang, L. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur. J. Pharm. Sci.,  2017, 110, 51-61.

[33]
Romero, A.; Rabinovich, M.G.; Vallejo, C.T.; Perez, J.E.; Rodriguez, R.; Cuevas, M.A.; Machiavelli, M.; Lacava, J.A.; Langhi, M.; Romero Acuña, L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J. Clin. Oncol.,  1994, 12(2), 336-341.
 [http://dx.doi.org/10.1200/JCO.1994.12.2.336] [PMID:  8113840]

[34]
Andersson, M.; Lidbrink, E.; Bjerre, K.; Wist, E.; Enevoldsen, K.; Jensen, A.B.; Karlsson, P.; Tange, U.B.; Sørensen, P.G.; Møller, S.; Bergh, J.; Langkjer, S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol.,  2011, 29(3), 264-271.
 [http://dx.doi.org/10.1200/JCO.2010.30.8213] [PMID:  21149659]

[35]
Janni, W.; Sarosiek, T.; Karaszewska, B.; Pikiel, J.; Staroslawska, E.; Potemski, P.; Salat, C.; Brain, E.; Caglevic, C.; Briggs, K.; DeSilvio, M.; Marini, L.; Papadimitriou, C. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res. Treat.,  2014, 143(3), 493-505.
 [http://dx.doi.org/10.1007/s10549-013-2828-z] [PMID:  24402830]

[36]
Awada, A.; Dirix, L.; Manso Sanchez, L.; Xu, B.; Luu, T.; Diéras, V.; Hershman, D.L.; Agrapart, V.; Ananthakrishnan, R.; Staroslawska, E. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann. Oncol.,  2013, 24(1), 109-116.

[37]
Li, Y.; Qiu, Y.; Li, H.; Luo, T.; Li, W.; Wang, H.; Shao, B.; Wang, B.; Ge, R. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. Front. Oncol.,  2021, 11664429.
 [http://dx.doi.org/10.3389/fonc.2021.664429] [PMID:  33996589]

[38]
Foucquier, J.; Guedj, M. Analysis of drug combinations: current methodological landscape. Pharmacol. Res. Perspect.,  2015, 3(3), 00149.
 [http://dx.doi.org/10.1002/prp2.149] [PMID:  26171228]

[39]
Pegram, M.D.; Konecny, G.E.; O’Callaghan, C.; Beryt, M.; Pietras, R.; Slamon, D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst.,  2004, 96(10), 739-749.
 [http://dx.doi.org/10.1093/jnci/djh131] [PMID:  15150302]

[40]
Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.E.; Blackwell, K.; Hoersch, S.; Xu, J.; Green, M.; Gianni, L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol.,  2017, 18(6), 732-742.
 [http://dx.doi.org/10.1016/S1470-2045(17)30312-1] [PMID:  28526536]

[41]
Krop, I.E.; Kim, S.B.; González-Martín, A.; LoRusso, P.M.; Ferrero, J.M.; Smitt, M.; Yu, R.; Leung, A.C.F.; Wildiers, H. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol.,  2014, 15(7), 689-699.
 [http://dx.doi.org/10.1016/S1470-2045(14)70178-0] [PMID:  24793816]

[42]
Yan, M.; Bian, L.; Hu, X.; Zhang, Q.; Ouyang, Q.; Feng, J.; Yin, Y.; Sun, T.; Tong, Z.; Wang, X.; Yao, H.; Zou, J.; Zhu, X.; Jiang, Z. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study. Transl. Breast Cancer Res.,  2020, 1, 13.
 [http://dx.doi.org/10.21037/tbcr-20-25]

[43]
Skokowa, J.; Dale, D.C.; Touw, I.P.; Zeidler, C.; Welte, K. Severe congenital neutropenias. Nat. Rev. Dis. Primers,  2017, 3(1), 17032.
 [http://dx.doi.org/10.1038/nrdp.2017.32] [PMID:  28593997]

[44]
Andreyev, J.; Ross, P.; Donnellan, C.; Lennan, E.; Leonard, P.; Waters, C.; Wedlake, L.; Bridgewater, J.; Glynne-Jones, R.; Allum, W.; Chau, I.; Wilson, R.; Ferry, D. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol.,  2014, 15(10), e447-e460.
 [http://dx.doi.org/10.1016/S1470-2045(14)70006-3] [PMID:  25186048]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115680096248592231016065117	Print ISSN 1568-0096
Publisher Name Bentham Science Publisher	Online ISSN 1873-5576

Current Cancer Drug Targets

The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract